On August 26, 2026 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to SOT106, the company’s potentially best-in-class investigational antibody-drug conjugate (ADC), for the treatment of soft tissue sarcoma, underscoring the urgency of developing new treatment options and the potential of SOT106 to address a significant unmet medical need.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SOT106 targets leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across multiple highly prevalent sarcoma subtypes, positioning it to potentially address a broad population of patients with limited therapeutic options.
"Soft tissue sarcomas (STS) remain a major unmet medical need, where decades of therapeutic progress have yet to translate into meaningful improvements for patients with advanced or recurrent disease," said Vivi Boura, M.D., chief medical officer of SOTIO. "Receiving Fast Track Designation for SOT106 is an important regulatory milestone that reinforces this program’s potential to improve outcomes for patients facing these difficult-to-treat cancers. As we advance SOT106 toward the clinic, we aim to translate its differentiated design and LRRC15-targeting strategy into a novel therapeutic approach with the potential to offer a new treatment option for patients across multiple soft tissue sarcoma subtypes."
Fast Track Designation is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs. The designation provides opportunities for more frequent interactions with the FDA and may support an accelerated pathway through eligibility for rolling review and Priority Review, if applicable criteria are met.
SOT106 has also received FDA Orphan Drug Designation for the treatment of osteosarcoma, further highlighting its potential across high-need sarcoma indications. SOTIO expects to initiate a first-in-human clinical trial later this year, marking the next key milestone in clinical development of SOT106.
(Press release, SOTIO, AUG 26, 2026, View Source [SID1234670375])